Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 13/20 | 0.34 |
| ▸ | CPB1 | P15086 | 8/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28344420 | 0.81 | CYP2C9 (0.44) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL28240322 | 0.80 | CYP2C9 (0.42) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL28483396 | 0.77 | CYP2C9 (0.40) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL5294922 | 0.76 | CYP2C9 (0.56) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL27635366 | 0.74 | CYP2C9 (0.46) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL28474358 | 0.74 | CYP2C9 (0.46) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Water SCHEMBL28942412 | 0.73 | CYP2C9 (0.45) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL16879897 | 0.73 | CPB2 (0.34) | CYP2C9CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL29175698 | 0.72 | TDP1 (0.46) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL28630919 | 0.72 | ALDH1A1 (0.36) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118660889-A | Salt and solid forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118525017-A | Quinoline compounds as KRAS inhibitors | 因赛特公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-110650976-B | Anti-SIRP alpha antibodies | 赛罗帕私人有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117897388-A | BTK protein degradation agent | 广州麓鹏制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-116685577-A | Preparation of benzimidazolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116406291-A | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-111526889-B | Methods of treating cancer using ATR inhibitors | 沃泰克斯药物股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115666565-A | Androgen receptor inhibitors for the treatment of non-metastatic castration resistant prostate cancer in subjects with severe liver damage | 阿拉贡药品公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109641885-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114787160-A | Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors | 因赛特公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113365623-A | Antiandrogen for treating metastatic castration sensitive prostate cancer | 阿拉贡药品公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-0800535-A1 | FIBRONECTIN ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020216-A1 | FIBRONECTIN ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |